Do oral ovulation induction agents offer benefits in women 38 to 43 years of age undergoing insemination cycles?

Naama Steiner, Jacob Ruiter‐Ligeti, Russell Frank, Maryam Al Shatti, Ahmad Badeghiesh, Keren Rotshenker-Olshinka, William Buckett, Michael H. Dahan
In: European Journal of Obstetrics & Gynecology and Reproductive Biology · 2021 · vol. 258 , pp. 273–277 · doi:10.1016/j.ejogrb.2021.01.012 · PMID:33486239 · W3120219503
article OA: closed CC0
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

This study investigated whether oral ovulation induction agents provide any benefit to women aged 38-43 undergoing insemination cycles.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

ObjectiveTo compare the success of ovulation induction using oral agents versus gonadotropins (GTs) in women ≥38 years old.Study designA retrospective cohort study was performed including all first to third stimulated IUI cycles conducted after the age of 38 years in a single academic fertility center between 01/2011 and 03/2018.ResultsA total of 1596 IUI cycles were included. 240 cycles were with clomiphene citrate (CC), 176 letrozole cycles and 1180 gonadotropin (GTs) cycles. The GTs group were older (p < 0.001), had lower antral follicular count (p < 0.001), and thicker endometrium (p < 0.001) compared to the oral agent groups. The letrozole group had a less mature follicles (p = 0.004) at the time of triggering compared to the other groups. No difference in pregnancy or clinical pregnancy rates was observed after controlling for confounders when comparing the 3-groups. 5 multiple pregnancies occurred, all in the GTs group. The groups were subdivided by age; 38-39 years old (N = 750) and 40-43 years old (N = 846). Nevertheless, no statistical difference was observed in pregnancy rates and clinical pregnancy rates between oral agents and GTs when controlling for the confounding effects among women at age 38-39 (p = 0.47, p = 1.0; respectively) and among women 40-43-years-old (p = 0.16, p = 1.0; respectively).ConclusionsClearly costs of oral agents are lower and they are more patient friendly than GTs, therefore oral agents should be first line for ovarian stimulation and IUI in women 38-43-years of age.

My notes (saved in your browser only)

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (1)

References (15)

Source provenance

openalex
last seen: 2026-05-11T05:40:41.230350+00:00
License: CC0 · commercial use OK